Clinical data | |
---|---|
AHFS/ Drugs.com | Consumer Drug Information |
MedlinePlus | a682022 |
Pregnancy category |
|
Routes of administration | By mouth ( tablets) |
ATC code | |
Pharmacokinetic data | |
Elimination half-life | 3–9 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.001.514 |
Chemical and physical data | |
Formula | C11H12N2O2 |
Molar mass | 204.229 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(verify) |
Ethotoin (previously marketed as Peganone) is an anticonvulsant drug used in the treatment of epilepsy. [1] It is a hydantoin, similar to phenytoin. It is not available in the United States.
The mechanism of action of ethotoin is similar to that of phenytoin.[ citation needed]
Ethotoin is indicated for tonic-clonic and partial complex seizures. [2]
Ethotoin is available in 250 mg tablets. [3] [4] It is taken orally in 4 to 6 divided doses per day, preferably after food.
Side effects include ataxia, visual disturbances, rash, and gastrointestinal problems.[ citation needed]
Ethotoin is synthesized by the reaction of benzaldehyde oxynitrile (2) with urea or ammonium bicarbonate, which forms an intermediate urea derivative (3) which on acidic conditions cyclizes to 5-phenylhydantoin (4). [5] Alkylation of this product using ethyl iodide leads to the formation of ethotoin (5).